Introduction
The clinical and pathological features of multiple sclerosis (MS) were ®rst described more than a century ago. Early studies pointed out the hallmarks of the disease, including demyelination and chronic in¯amma-tion in the central nervous system (CNS) white matter. Clinical, imaging and pathological studies have provided insight into possible disease mechanisms operative in MS pathogenesis. They have clearly demonstrated that in most patients, MS is a disease with acute onset accompanied by active in¯ammation and demyelination. Although axonal degeneration is seen early during the disease, the extent and chronicity of in¯ammation in MS is clearly different from primary neurodegenerative disorders or acute brain tissue damage. Despite major research efforts within the past few decades, the etiology of MS is still unknown. However, a variety of recent ®ndings in MS and its animal models have contributed to our understanding of disease pathogenesis, and have provided a basis for new therapeutic concepts.
Experimental autoimmune encephalomyelitis paradigms in multiple sclerosis
Experimental autoimmune encephalomyelitis (EAE) has been one of the most valuable autoimmune models, providing insights into many mechanisms during physiological and pathological immune responses [1] . Classical EAE is induced in susceptible animal strains (i.e. Lewis rats) by immunization with myelin antigens and Freund's adjuvant. The disease is usually monophasic with spontaneous remission. EAE has been extensively characterized during the past two decades providing evidence that it can be transferred by CD4 myelin-speci®c T cells. The immune dynamics in vivo have been elucidated through an elegant approach with genetically altered T cell clones in an adoptive transfer rat model [2
. . ]. The study demonstrates that after cell transfer a priming of T cells in lymph nodes and the spleen is necessary before these cells collectively migrate to the brain, mediate in¯ammation and subsequently undergo cell death.
Although only a minority of myelin-speci®c T cell clones can transmit disease those cells were thought to belong to the T helper type 1 subtype characterized by the secretion of IL-2, IFN-g and TNF-a. Furthermore, the secretion of TNF-a, a proin¯ammatory cytokine, was considered crucial for the encephalitogenicity of the T cell clones [1] . In contrast, blocking TNF pathways and polarizing T cell responses towards a T helper type 2 phenotype (secretion of was shown to be of therapeutic bene®t in most EAE models. This EAE concept has been applied to the human disease classifying MS as a prototypic T helper type 1 disorder and TNF-a as a key player in the cascade of events leading to demyelination [1] . Similarly, TCRBV expression differences between CSF and blood were primarily observed on CD8 T cells and only rarely on CD4 T cells. The TCRBV expression differences were shown to be stable over time, and involved expansion of T cells with highly similar or identical T cell receptor alpha and beta chains. In both studies, the expanded TCRBV chains were not found among peripheral blood T cells. Both studies formally demonstrate a speci®c clonal and oligoclonal accumulation of CD8 T cells in the CNS of MS patients. Although the role of these cells in the pathogenesis of MS is unknown, it is likely that they target speci®c antigens in the brain.
The discussion about the role of CD8 T cells in MS has been further stimulated by recent ®ndings in EAE [16] . In the study by Sun and colleagues [17 . ] progressive and destructive EAE was induced by puri®ed myelinspeci®c CD8 T cells. Similarly, Huseby and colleagues [18 . . ] induced EAE by the adoptive transfer of CD8 T cell clones speci®c for a myelin basic protein peptide. Although disease was induced after irradiation of recipient animals, the adoptive transfer of T cell clones proved the encephalitogenicity of myelin-speci®c CD8 T cells. Interestingly, in this model, lesions were primarily located in the brain, not in the spinal cord as seen in most EAE models induced by CD4 T cells, and characterized by little in¯ammation, but massive perivascular cell death and demyelination.
The come-back of the B cell
The potential pathogenic role of antibodies has been discussed since the discovery of the intrathecal immunoglobulin synthesis in MS [19 . , 20] . Indeed, the occurrence of elevated antibody levels and oligoclonal IgG bands in the CSF is still the only valuable immune parameter in the diagnosis of MS. The antibody response in MS patients seems to be remarkably stable over long periods of time, suggesting that it is focused on few target antigens without major changes during the disease course. This ®nding is also re¯ected by studies investigating the local B cell response in MS patients. Several investigators demonstrated the occurrence of clonal B cell accumulation in the CSF or lesions of MS patients by analysing the heavy-chain variable region genes [19 . ,21] . All studies identi®ed restricted dominant use or the overexpression of certain heavy-chain variable region genes in the diseased organ compartment. Furthermore, the studies demonstrated somatic hypermutations and replacement mutations in the heavy-chain variable region genes compatible with af®nity maturation of the antibody response. Such changes were not or were to a much lesser extent identi®ed in the peripheral blood of MS patients [22] . The ®ndings are consistent with the occurrence of an oligoclonal IgG synthesis in CSF, and suggest that the humoral immune response focuses on a few as yet unknown CNS resident antigens. However, similar to the studies on clonal T cell expansion in the CNS, none of the studies has provided evidence that determines whether this is the result of an ongoing active immune response in the CNS or is only simply caused by resident memory cells. Such information can only be provided by serial analysis of CSF or brain tissue to identify the persistence of clonotypes and ongoing antigen receptor maturation of B cells. Nevertheless, the B cell features in MS are very similar to antibody responses seen in chronic infectious diseases of the CNS, in which the local humoral immune response targets disease-associated antigens derived from the causative agent [23 . . ]. One study addressed the speci®city of the local antibody response in MS by engineering clonally expanded heavy and light chain genes from lesions into whole human IgG [24] . By screening expression libraries and oligodendroglioma cell lines the authors found reactivity with double-stranded DNA. However, this ®nding has not been con®rmed by other groups nor validated in other MS patients.
The general role of antibodies for disease progression has been addressed in EAE and MS. Iglesias and colleagues [25] have clearly shown that myelin-speci®c antibodies can enhance disease severity in EAE. Similarly, it seems that high intrathecal antibody production is a negative predictor for disease progression [26] . More recently, Cepok and colleagues [27 . ] provided evidence for a possible correlation between intrathecal B cell dominance and disease progression.
Regulatory cells and their therapeutic potential
Besides a potentially harmful T and B cell response, it is likely that regulatory immune responses play a signi®-cant role in the development of MS. In particular, natural killer (NK) T cells have received attention in studies on MS and EAE. NK T cells constitute a population of T cells that share surface markers and characteristics with NK cells [28] . The cell population expresses a heavily biased T cell receptor repertoire (Va14, Vb2, 7, or ]. The therapeutic potency of glycosphingolipids is of particular importance because these ligands can also activate human NK T cells, thus providing a promising approach to treat MS. Moreover, following the altered peptide ligand concept with peptide antigens, altered glycosphingolipids have been designed that preferentially induce T helper type 2 cytokines [33 . . ] . Although the concept of treating MS by enhancing regulatory T cells seems attractive, evidence from human studies is necessary to address the role of NK T cells in MS pathogenesis and provide evidence that driving immune responses towards a T helper type 2 response is bene®cial.
Mechanisms in the local environment
The introduction of new technologies has allowed dissection of the histology and molecular biology of MS lesions. The discovery of heterogeneity in demyelinating lesions has suggested that different mechanisms may be involved in MS pathogenesis [36] . This observation may be important for future studies on the etiology and therapy of disease [37] . However, the potential to apply these ®ndings to the clinic will rely on the development of technologies that allow the strati®-cation of MS subtypes without being dependent on brain biopsies [27 . ,38 . ]. The use of new technologies also allowed dissection of the local immune response in MS brain lesions. The studies contributed signi®cantly to the discovery of clonal T and B cell expansions (see above), and provided information about the local environment in EAE and MS lesions. The ®rst studies using immunohistochemistry and the quantitative polymerase chain reaction technique demonstrated that a variety of cytokines are upregulated in MS brain lesions, among them T helper types 1 and 2 cytokines [39, 40] . The ®ndings were extended by microarray studies on RNA expression levels, comparing lesions with normal appearing white matter in MS and EAE [41, 42, 43 . ]. Those studies demonstrated the complexity of gene regulation in MS lesions. Further investigations are necessary and need to be complemented by other approaches to evaluate the role of the identi®ed genes in disease pathogenesis. In addition, microarray technology has reached clinical studies to monitor immune changes after immunomodulatory treatment of MS patients [44 . ]. In a ®rst study, Chabas and colleagues [45
. . ] used a large-scale sequencing approach on complementary DNA libraries from two MS patient samples and a control sample to search for genes expressed in MS lesions but not in normal white matter. The investigators identi®ed more than 50 genes that were expressed at a signi®cantly higher level in MS lesions, among them osteopontin, a proin¯ammatory cytokine involved in T cell activation. The presence of osteopontin was con®rmed in MS lesions by immunohistochemistry. Interestingly, osteopontin knockout mice were less susceptible to myelin±oligodendrocyte glycoprotein (MOG)-induced EAE than wild-type controls. As the study did not determine whether the upregulation of osteopontin was speci®c for MS lesions or seen in any CNS in¯ammatory disease, the results do not enable us to conclude that osteopontin is unique to MS lesions. However, to research in humans with novel technologies and to con®rm the biological relevance of candidate molecules in animal models provides a new and highly promising strategy to decrypt the pathology of MS.
Conclusion
Recent studies have provided strong evidence that the immunology of MS is much more complex than previously hypothesized. Although CD4 T helper type 1 T cells may play an important role, a variety of other immune cells including B cells, CD8 T cells and NK T cells, seem to be essentially involved in disease pathogenesis by inducing or controlling the immune response in the CNS of MS patients. Evidence from recent studies suggests that the speci®c local humoral and cellular immune response is highly focused, which may mean that in individual patients only a limited number of antigens are targeted [14, 15 . ,19 . ]. However, it is still unclear which antigens are recognized and whether this is a primary or a secondary disease event. Further studies involving cutting edge technologies [21, 43 . ,45 . . ,46] will hopefully clarify which antigens are responsible for the chronic in¯ammatory activity seen in MS patients. The results of these studies in combination with the use of improved animal models [47, 48] may provide a better basis for future speci®c immune intervention strategies in MS. 
